RTP Mobile Logo
Submitted by web@researchtop... on Mon, 01/29/2018 - 15:56

Interview with Edward A Stadtmauer, MD

Track 1: Evolution of B-cell maturation antigen (BCMA) targeting in multiple myeloma (MM)
Track 2: Chimeric antigen receptor (CAR) T-cell therapy-associated cytokine release syndrome and neurotoxicity
Track 3: Clinical management of cytokine release syndrome
Track 4: Durable remissions with BCMA CAR T-cell therapy in relapsed/refractory (R/R) MM
Track 5: Initial efficacy and safety results with BCMA CAR T-cell therapy
Track 6: Feasibility of administering CAR T-cell therapy in a community setting
Track 7: Mechanism of action of monoclonal antibodies; daratumumab-associated infusion-related reactions
Track 8: Subcutaneous delivery of daratumumab
Track 9: Case: A 56-year-old man with R/R MM and t(11;14) receives venetoclax/bortezomib/dexamethasone
Track 10: Case: A 54-year-old man with R/R MM receives ixazomib/lenalidomide/dexamethasone
Track 11: Treatment approach for patients who experience relapse while receiving post-transplant lenalidomide maintenance therapy
Track 12: Case: A 76-year-old man with previously treated Waldenström macroglobulinemia (WM) experiences a prolonged response to ibrutinib

Interview with Sarah A Holstein, MD, PhD

Track 1: Case: A 58-year-old man with newly diagnosed high-risk MM experiences a very good partial response and moderate peripheral neuropathy with lenalidomide/bortezomib/dexamethasone (RVd) induction → autologous stem cell transplant (ASCT) but is unwilling to receive bortezomib maintenance therapy because of concerns about further neuropathy
Track 2: Ixazomib as a component of maintenance therapy for high-risk MM
Track 3: Benefits of post-transplant maintenance therapy
Track 4: RVd consolidation and maintenance therapy for high-risk MM
Track 5: Selecting among options for maintenance therapy
Track 6: Ixazomib-associated gastrointestinal toxicity
Track 7: Carfilzomib- versus bortezomib-based induction therapy
Track 8: Duration of lenalidomide maintenance therapy
Track 9: Early versus delayed ASCT after induction therapy for MM
Track 10: Clinical utility of minimal residual disease (MRD) assessment in MM
Track 11: Case: A 59-year-old man with R/R MM and high-risk cytogenetics receives pomalidomide/daratumumab/dexamethasone
Track 12: Triplet therapy options for R/R disease
Track 13: Advantages of subcutaneous daratumumab
Track 14: Case: A 41-year-old woman presents with lambda light chain MM and bone marrow amyloidosis
Track 15: Case: A 72-year-old man develops myelodysplastic syndrome after receiving post-transplant consolidation RVd and subsequently receives multiple lines of therapy for R/R disease
Track 16: Case: A 52-year-old woman initially diagnosed with smoldering MM presents with widespread bone disease
Track 17: Updated IMWG (International Myeloma Working Group) criteria on risk stratification in MM
Track 18: Management of high-risk R/R MM that progresses rapidly on triplet therapy
Track 19: Activity and tolerability of panobinostat in combination with carfilzomib/dexamethasone
Track 20: Status of the Phase III KEYNOTE-183 and 185 trials: Pembrolizumab in combination with an immunomodulatory drug (IMiD) and dexamethasone

Interview with Paul G Richardson, MD

Track 1: Recent therapeutic advances in MM
Track 2: Changing landscape of smoldering MM
Track 3: Impact of cytogenetics on treatment choice
Track 4: Bisphosphonate therapy in MM
Track 5: Role of histone deacetylase inhibitors in the treatment of MM
Track 6: Correlation between CD38 expression levels and response to daratumumab
Track 7: Optimizing the frequency and convenience of daratumumab administration
Track 8: Clinical experience with the investigational anti-CD38 monoclonal antibody isatuximab
Track 9: ICARIA-MM: An ongoing Phase III trial of pomalidomide and dexamethasone with or without isatuximab for R/R MM
Track 10: Sequencing of therapies to achieve optimal outcomes in MM
Track 11: Recognition and management of immune paresis
Track 12: Potential utility of elotuzumab in combination with lenalidomide in the maintenance setting
Track 13: Toxicities associated with long-term single-agent lenalidomide maintenance therapy; management of lenalidomide-associated diarrhea
Track 14: Recent FDA approval of ibrutinib for chronic graft-versus-host disease
Track 15: Potential of ibrutinib-based combinations for R/R MM
Track 16: Activity and side effects of CAR T-cell therapy in MM
Track 17: Promising therapeutic vaccines and antibodies for MM
Track 18: Effectiveness and tolerability of the investigational proteasome inhibitor marizomib for central nervous system MM and malignant glioblastoma
Track 19: Activity of melflufen, a peptidase-activated derivative of melphalan
Track 20: IFM/DFCI 2009 Phase III trial results: RVd with or without ASCT for newly diagnosed MM
Track 21: Case: A 70-year-old woman with high-risk MM and bone metastases receives daratumumab on a clinical trial after disease progression on multiple lines of therapy
Track 22: Case: A 61-year-old man with R/R MM receives ixazomib/lenalidomide/dexamethasone on a clinical trial
Track 23: Case: A 64-year-old man with R/R MM and bone metastases harbors a 13q deletion abnormality
Track 24: Venetoclax for MM with or without t(11;14)
Track 25: Comparison of proteasome inhibitors for MM

Interview with Shaji K Kumar, MD

Track 1: Improving outcomes for newly diagnosed amyloid light chain (AL) amyloidosis
Track 2: Investigational strategies for the treatment of AL amyloidosis; factors predicting organ response
Track 3: Presentation and treatment of localized AL amyloidosis
Track 4: Advances in the treatment of WM
Track 5: Incorporation of ibrutinib into the treatment of WM
Track 6: Guiding principles in the treatment of WM
Track 7: Diagnosis and management of smoldering MM
Track 8: ASCENT Phase II study of carfilzomib/lenalidomide/dexamethasone and daratumumab with or without ASCT for patients with high-risk smoldering MM
Track 9: MRD testing in MM and its application in clinical trials and practice
Track 10: MRD negativity after induction therapy and prediction of benefit from transplant
Track 11: Importance of risk stratification in the selection of initial therapy for MM
Track 12: Carfilzomib-associated cardiac dysfunction and dyspnea
Track 13: Advances in the treatment of R/R MM
Track 14: Principles guiding the sequencing of therapies for R/R MM
Track 15: Treatment approach for lenalidomide-refractory relapsed MM
Track 16: Incorporating ixazomib into the treatment algorithm for R/R MM
Track 17: ELOQUENT-2 Phase III trial of elotuzumab/lenalidomide and dexamethasone for R/R MM
Track 18: Evaluation of elotuzumab as part of induction and/or maintenance therapy
Track 19: Therapeutic options for patients with disease that is not refractory to lenalidomide or bortezomib or both
Track 20: Choice of proteasome inhibitor in the relapsed setting
Track 21: Options for patients with “double-refractory” MM
Track 22: Venetoclax for patients with heavily pretreated t(11;14) MM
Track 23: PCR-based assay for Bcl-2 and association with response to venetoclax
Track 24: BCMA CAR T-cell therapy in MM
Track 25: Combining immune checkpoint inhibitors with IMiDs
Track 26: ASCT for relapsed MM
 
FACULTY
 
Edward A Stadtmauer, MD
Professor of Medicine
Leader, Hematologic Malignancies Program
Director, Bone Marrow and
Stem Cell Transplant Program
Division of Hematology-Oncology
Abramson Cancer Center of the
University of Pennsylvania
Philadelphia, Pennsylvania
 
Sarah A Holstein, MD, PhD
Associate Professor
Division of Oncology and Hematology
Department of Internal Medicine
University of Nebraska
Medical Center
Omaha, Nebraska
 
Paul G Richardson, MD
Clinical Program Leader
Director of Clinical Research
Jerome Lipper Multiple Myeloma Center
Department of Medical Oncology
Dana-Farber Cancer Institute
RJ Corman Professor of Medicine
Harvard Medical School
Boston, Massachusetts
 
Shaji K Kumar, MD
Professor of Medicine
Consultant
Division of Hematology and Blood
and Marrow Transplantation
Mayo Clinic
Rochester, Minnesota
 
EDITOR
 
Neil Love, MD
Research To Practice
Miami, Florida